Kean Birch — Rethinking Value in the Bio-economy: Finance, Assetization, and the Management of Value

Yield

28 of 215 paragraphs kept (13.0%). Target: 35%+ — ⚠️ BELOW target.

Thesis

Value is not inherent in things but achieved through capitalization practices. · ch. 0

Argument

1. Over a third of UK listed biotech firms collapsed after the 2008 financial crisis. — ch. 0
2. The VC-to-IPO model dominates bio-economy discourse but not actual financing — ch. 0
3. Value in the bio-economy is produced through valuation practices, not intrinsic to biological matter. — ch. 0
4. Capitalization builds the thing being valued at the same time it appraises that thing — ch. 0
5. Understanding value requires studying the assets underpinning firm valuation, not commodity production. — ch. 1
6. Monopoly rent discounts the future in favor of the past — ch. 1
7. An asset is property yielding an income stream, unlike a commodity for sale. — ch. 1
8. Asset value is constituted by active management within organizations, not by biological properties. — ch. 1
9. Assetization of IP reduces incentives to develop actual products — ch. 1
10. Life sciences firms may never produce products, so valuation is prospective rather than embodied — ch. 1
11. Asset value is actively managed, including downward, and its constructedness is obscured. — ch. 1
12. Accounting practices involve interpretation and are not straightforwardly performative — ch. 1
13. Analyzing bio-economy value requires focusing on assets rather than commodities — ch. 1
14. Accounting for biological assets reflects chosen methods, not intrinsic biological qualities — ch. 2
15. Intangible asset value is constituted by intermediary actors who represent investors. — ch. 2
16. Biotech firms can be valued as strategic acquisitions, not for their revenue — ch. 2
17. Life science firm value is managed through strategic information release. — ch. 2
18. Value in the bio-economy is managed through asset governance, not product sales. — ch. 2
19. Listed firms’ value depends on sustained investor relationship building. — ch. 2
20. Value is constituted by knowledge and practice, not merely hype. — ch. 2
21. Asset value derives from future earnings rather than intrinsic commodity value — ch. 2
22. In the bioeconomy, informational signaling about assets, not product sales, constitutes firm value. — ch. 2
23. Capitalization scholarship often treats capital as a living thing embodied in commodities. — ch. 3
24. Value in the bio-economy is better theorized through assetization than commodification. — ch. 3
25. Bio-economy valuation practices are not peculiar to that sector. — ch. 3
26. Market makers profit from the buy-sell spread by providing liquidity. — ch. 3
27. Understanding value as assetization requires analyzing political economy, not just applying STS to finance. — ch. 3

Annotation Roundup

Question

• Over a third of UK listed biotech firms collapsed after the 2008 financial crisis. — Which companies survived and why? A survival analysis of the UK biotech bust would test the article’s assetization thesis against which firms kept their financing.
• The VC-to-IPO model dominates bio-economy discourse but not actual financing — What does actually finance bio-economy firms if not VC? Worth chasing down Birch’s arguments since this bears directly on the assetization debate.
• Accounting practices involve interpretation and are not straightforwardly performative — Worth chasing: what exactly distinguishes MacKenzie’s ‘interpretive’ accounting from Callon’s performativity?
• Asset value is actively managed, including downward, and its constructedness is obscured. — The claim that value creation ‘tends to be denied’ invites exploring case-level evidence: do bioeconomy firms explicitly obscure value-reduction strategies in investor communications, or is the denial more diffuse?
• Analyzing bio-economy value requires focusing on assets rather than commodities — The shift from commodities/commodification to assets/assetization marks a real epistemological break in STS literature worth chasing down in the cited works (Muniesa, Doganova). Xref
• Over a third of UK listed biotech firms collapsed after the 2008 financial crisis. — Connects to the financialization of science literature and to the dot-com bubble’s biotech equivalents — plausibly resonates with a finance-library reader’s work on distressed R&D-heavy sectors.
• Capitalization builds the thing being valued at the same time it appraises that thing — Directly connects to the reading purpose: this is the core conceptual framing of assetization literature (Muniesa, Birch on biotechnology).
• Value is not inherent in things but achieved through capitalization practices. — Connects to the assetization debate and Muniesa’s larger program on valuation as practice; also brushes against Marxian use-value critique.
• Life sciences firms may never produce products, so valuation is prospective rather than embodied — Contrasts with commodity-production frameworks of classical political economy that anchor value in embodied labor.
• An asset is property yielding an income stream, unlike a commodity for sale. — Cleanly parallels the music copyright vs. CD example with the commodification/assetization divide the reader is tracking.
• Asset value is constituted by active management within organizations, not by biological properties. — This reframing connects to the financialization literature where value is made through organizational practices, accounting conventions, and investor relations rather than material production.
• Monopoly rent discounts the future in favor of the past — Connects to the Birthe & Muniesa assetization literature and to Kalecki/classical rent theory.
• Assetization of IP reduces incentives to develop actual products — Directly relevant to the reader’s foundational assetization work; the paradox (IP income crowds out product development) resonates with finance-of-innovation critiques like Mazzucato’s entrepreneurial state.
• Biotech firms can be valued as strategic acquisitions, not for their revenue — Connects to research on exit strategies in VC financing and the distinction between strategic (trade) sales and financial (IPO) exits in assetization debates.
• Accounting for biological assets reflects chosen methods, not intrinsic biological qualities — Parallels the reader’s existing work on trees as underused infrastructure, which treats biological assets as mattering rather than inert.
• Intangible asset value is constituted by intermediary actors who represent investors. — Resonates with the assetization literature (Birch, Muniesa) and the idea of value as performed rather than intrinsic — links to the foundational assetization debate framing of this reading.
• Value is constituted by knowledge and practice, not merely hype. — Connects to the assetization debate and to network/relational theories of value (e.g., Callon, Latour) where value is performed rather than intrinsic.
• Listed firms’ value depends on sustained investor relationship building. — Direct evidence for the assetization claim that value is performed through relational practices like investor relations, not intrinsic to the underlying asset.
• In the bioeconomy, informational signaling about assets, not product sales, constitutes firm value. — This is the core claim of the assetization thesis the reader is studying — assetization displaces commodification as the operative regime of value.
• Value in the bio-economy is better theorized through assetization than commodification. — Connects directly to the foundational assetization debate in finance/STS scholarship (Birch, Muniesa, Pistor on valuation as social practice).
• Understanding value as assetization requires analyzing political economy, not just applying STS to finance. — Connects directly to the reader’s assetization foundational reading purpose; the distinction from social studies of finance is a key framing point for the assetization literature.
• Capitalization scholarship often treats capital as a living thing embodied in commodities. — Connects to the reader’s assetization debate — this framing of capitalization-as-embodied-lively-capital is precisely what assetization theory challenges.
• Bio-economy valuation practices are not peculiar to that sector. — A key move in the assetization debate: assetization isn’t bio-economy-specific; connects to the reader’s cross-sector assetization framing.
• Market makers profit from the buy-sell spread by providing liquidity. — Distinguishes the financial market-making sense from the assetization sense — directly relevant to the foundational assetization article. Seed
• Asset value is actively managed, including downward, and its constructedness is obscured. — An angle: how intangible asset value is manufactured not discovered — the accounting tricks, relabeling, and governance practices that conjure value on a balance sheet.
• Life science firm value is managed through strategic information release. — Article angle: how ‘managing sentiment’ as a valuation practice parallels brand/PR performance in attention economies more broadly. Define
• Value in the bio-economy is produced through valuation practices, not intrinsic to biological matter. — Sets up the central intervention: value as managed/constructed through valuation practices (financialization, capitalization, assetization) rather than inherent in biological materiality — the core definitional move of the assetization debate.
• Capitalization builds the thing being valued at the same time it appraises that thing — Defines capitalization as a dual process where appraisal and construction are simultaneous — the foundational move of the assetization debate.
• Value is not inherent in things but achieved through capitalization practices. — Defines the core thesis of the assetization debate: value as social achievement rather than latent property.
• Accounting practices involve interpretation and are not straightforwardly performative — Contrasts the performativity thesis (Callon) with MacKenzie’s interpretive view of accounting — key framework distinction.
• An asset is property yielding an income stream, unlike a commodity for sale. — The core asset/commodity distinction — asset yields income stream, commodity is sold — is the foundational definition anchoring the whole assetization debate.
• Asset value is constituted by active management within organizations, not by biological properties. — Here the author redefines assetization as fundamentally a management-and-governance process, inverting the dominant bioeconomy framing that locates value in biological matter or liveliness itself.
• Assetization of IP reduces incentives to develop actual products — Introduces the key analytic pairing of ‘assetization of knowledge’ and ‘monetization of that knowledge asset’ central to the assetization debate.
• Asset value derives from future earnings rather than intrinsic commodity value — Clarifies the core assetization shift: value is constituted by valuation practices on a firm, not latent in a commodity.
• Intangible asset value is constituted by intermediary actors who represent investors. — Clarifies the concept of a ‘financial ecosystem’ — who the actors are and how they jointly constitute intangible value.
• Value is constituted by knowledge and practice, not merely hype. — Defines ‘materiality’ as the load-bearing concept: disclosure of information that then feeds valuation judgments.
• Life science firm value is managed through strategic information release. — Defines ‘financial materiality’ and ‘managing sentiment’ as core practices in how value is constructed for assetized firms lacking trading earnings.
• In the bioeconomy, informational signaling about assets, not product sales, constitutes firm value. — Defines the theoretical move: valuation in the bioeconomy is constituted by information about assets rather than by realized commercial output.
• Understanding value as assetization requires analyzing political economy, not just applying STS to finance. — Defines what a political-economy approach to value-as-assetization entails versus merely studying finance as a new STS topic.
• Capitalization scholarship often treats capital as a living thing embodied in commodities. — Distinguishes the ‘capitalization’ concept as used in STS bio-economy scholarship from a market-maker definition of value.
• Market makers profit from the buy-sell spread by providing liquidity. — Clean working definition of a market maker, contrasted against the loose STS use of ‘capitalization’.